Content area

Abstract

Sage Therapeutics Inc (SAGE) - Pharmaceuticals and Healthcare Product Pipeline

Summary

Sage Therapeutics Inc (Sage) is a clinical-stage biopharmaceutical company that discovers, develops and markets drugs for the treatment of central nervous system (CNS) disorders. It develops drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors of NMDA and GABA. Its flagship product Zulresso (brexanolone) is a proprietary intravenous (IV) formulation administered for the treatment of postpartum depression (PPD).

This report provides outline on pipeline products by Number of Pipeline Products by Therapy Area, Indication, development stage and Partnered/Out-Licensed Products.

This report is built using information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Details

1007133
Company / organization
Title
Sage Therapeutics Inc (SAGE)
Publication title
Number of pages
161
Publication year
2025
Publication date
2025
Publisher
GlobalData plc
Place of publication
London
Country of publication
United Kingdom
Publication subject
Source type
Report
Language of publication
English
Document type
Company Profile
Document feature
Tables; Graphs; Company description; Company financials; Company competitors; Company SWOT
ProQuest document ID
2454568674
Document URL
https://www.proquest.com/reports/sage-therapeutics-inc/docview/2454568674/se-2?accountid=208611
Copyright
Copyright GlobalData plc 2025
Last updated
2025-08-29
Database
ProQuest One Academic